Progesterone bioavailability with a progesterone-releasing silicone vaginal ring in IVF candidates

European Journal of Medical Research

Volumn 12, Issue 6, 2007, Pages 264-267

  Dragonas, C ^a   Maltaris, T ^a   Binder, H ^a   Kat, M ^a   Mueller, A ^a   Cupisti, S ^a   Hoffmann, I ^a   Beckmann, M W ^a   Dittrich, Ralph ^a  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

Author keywords

Ferlitility; IVF; Luteal phase support; Progesterone; Vaginal ring

Indexed keywords

BARIUM SULFATE; DECAPEPTYL DEPOT; ESTRADIOL; GONADORELIN DERIVATIVE; GONADOTROPIN; POLYMER; PROGESTERONE; SILICON; TRIPTORELIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL ARTICLE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG INDUSTRY; DRUG RELEASE; FEMALE; FERTILIZATION IN VITRO; FIRST PASS EFFECT; HORMONE DEFICIENCY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; OVULATION INDUCTION; VAGINA RING;

ADMINISTRATION, INTRAVAGINAL; ADULT; BIOLOGICAL AVAILABILITY; DRUG DELIVERY SYSTEMS; FEMALE; FERTILIZATION IN VITRO; HUMANS; PROGESTERONE; PROGESTINS; SILICONES;

EID: 34547880066     PISSN: 09492321     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Hughes EG, Fedorkow DM, Daya S, Sagle MA, Van de Koppel P, Collins JA. The routine use of gonadotropin-releasing hormone agonists prior to in vitro fertilization and gamete intrafallopian transfer: a meta-analysis of randomized controlled trials. Fertil Steril. 1992 Nov; 58(5): 888-96.
2. Penzias AS. Luteal phase support. Fertil Steril. 2002 Feb; 77(2): 318-23.
3. Friedler S, Raziel A, Schachter M, Strassburger D, Bukovsky I, Ron-El R. Luteal support with micronized progesterone following in-vitro fertilization using a down-regulation protocol with gonadotrophin-releasing hormone agonist: a comparative study between vaginal and oral administration. Hum Reprod. 1999 Aug; 14(8): 1944-8.
4. Miles RA, Paulson RJ, Lobo RA, Press MF, Dahmoush L, Sauer MV. Pharmacokinetics and endometrial tissue levels of progesterone after administration by intramuscular and vaginal routes: a comparative study. Fertil Steril. 1994 Sep; 62(3): 485-90.
5. Cicinelli E, Cignarelli M, Sabatelli S, Romano F, Schonauer LM, Padovano R, Einer-Jensen N. Plasma concentrations of progesterone are higher in the uterine artery than in the radial artery after vaginal administration of micronized progesterone in an oil-based solution to postmenopausal women. Fertil Steril. 1998 Mar; 69(3): 471-3.
6. Zegers-Hochschild F, Balmaceda JP, Fabres C, Alam V, Mackenna A, Fernandez E, Pacheco IM, Sepulveda MS, Chen S, Borrero C, Borges E. Prospective randomized trial to evaluate the efficacy of a vaginal ring releasing progesterone for IVF and oocyte donation. Hum Reprod. 2000 Oct; 15(10): 2093-7.
7. Maruo T, Mishell. DR, Ben-Chetrit A, Hochner-Celnikier D, Hamada AL, Nash HA. Vaginal rings delivering progestrone and estradiol may be a new method of hormone replacement therapy. Fertil Steril. 2002 Nov; 78(5): 1010-6.
8. Hamada AL, Maruo T, Samoto T, Yoshida S, Nash H, Spitz IM, Johansson E. Estradiol/progesterone-releasing vaginal rings for hormone replacement therapy in post-menopausal women. Gynecol Endocrinol. 2003 Jun; 17(3):247-54.
9. Weisberg E, Ayton R, Darling G, Farrell E, Murkies A, O'Neill S, Kirkegard Y, Fraser IS. Endometrial and vaginal effects of low-dose estradiol delivered by vaginal ring or vaginal tablet. Climacteric. 2005 Mar; 8(1): 83-92.
10. Johnston A. Estrogens - pharmacokinetics and pharmacodynamics with special reference to vaginal administration and the new estradiol formulation: Estring. Acta Obstet Gynecol Scand Suppl. 1996; 163: 16-25.
11. Ben-Chetrit A, Hochner-Celnikier D, Lindenberg T, Zacut D, Shimonovitz S, Gelber H, Spitz IM. Vaginal ring delivering estradiol and progesterone: a possible alternative to relieve climacteric symptoms. Isr Med Assoc J. 2005 May; 7(5): 302-6.
12. Devroey P, Smitz J, Bourgain C, Camus M, Van Steirteghem A. [Micronized progesterone is the method of choice as supplementation therapy in LHRH-agonist superovulated cycles; in French.] Contracept Fertil Sex (Paris). 1991; 19: 7-8.
13. Kiesel L, Runnebaum B. [Gonadotropin-releasing hormone and analogs: physiology and pharmacology; in German.] Gynäkol Geburtshilfliche Rundsch. 1992; 32(1): 22-30.
14. Bulletti C, de Ziegler D, Flamigni C, Giacomucci E, Polli V, Bolelli G, Franceschetti F. Targeted drug delivery in gynaecology: the first uterine pass effect. Hum Reprod. 1997 May; 12(5): 1073-9.
15. Cicinelli E, de Ziegler D, Bulletti C, Matteo MG, Schonauer LM, Galantino P. Direct transport of progesterone from vagina to uterus. Obstet Gynecol. 2000 Mar; 95(3): 403-6.
16. Zegers-Hochschild, F. The normal menstrual cycle. In: Rowe PJ, Vikhlyaeva EM, eds. Diagnosis and treatment of infertility. Toronto: Huber, 1988: 137.
17. Sarkar NN. Low-dose intravaginal estradiol delivery using a Silastic vaginal ring for estrogen replacement therapy in postmenopausal women: a review. Eur J Contracept Reprod Health Care. 2003 Dec; 8(4): 217-24.
18. Henriksson L, Stjernquist M, Boquist L, Cedergren I, Selinus I. A one-year multicenter study of efficacy and safety of a continuous, low-dose, estradiol-releasing vaginal ring (Estring) in postmenopausal women with symptoms and signs of urogenital aging. Am J Obstet Gynecol. 1996 Jan; 174: 85-92.